Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel pleuromutilin derivate, preparation method and medical use thereof

A technology of pleuromutilin and derivatives, which is used in pharmaceutical formulations, antibacterial drugs, drug combinations, etc.

Active Publication Date: 2011-11-02
南通药享科技有限公司
View PDF6 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] Referring to the structure-activity relationship and the latest research progress of pleuromutilin derivatives, we analyzed the structural characteristics of typical anti-drug-resistant bacteria drugs, and designed thiazole pleuromutilin derivatives to obtain the antibacterial activity of pleuromutilin. A better compound, the present invention discloses a class of novel pleuromutilin derivatives with medicinal value and pharmaceutically acceptable salts thereof, and there is no report on such compounds so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel pleuromutilin derivate, preparation method and medical use thereof
  • Novel pleuromutilin derivate, preparation method and medical use thereof
  • Novel pleuromutilin derivate, preparation method and medical use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] 14-Deoxy-[(2-(p-toluenesulfonyloxy)acetoxy]-mutriptyline (2) Preparation

[0093] Dissolve 20 g (52.9 mmol) of pleuromutilin in 160 mL of 1,2-dichloroethane, and then add 12 mL (86.6 mmol) of triethylamine to obtain a yellow clear liquid. Add 14 g (73.7 mmol) of p-toluenesulfonyl chloride and react at room temperature (20°C). As the reaction progresses, the solution gradually turns yellow and turbid. After 17 h, the reaction was complete. After stopping the stirring, let it stand still, remove the solid by filtration, wash the filtrate twice with water until pH = 7, and dry it with anhydrous sodium sulfate. The solution was vortexed until dry, and a large amount of white matter was produced. The resulting solid was recrystallized from ethyl acetate, and filtered with suction to obtain 14.2 g of a white solid. Yield: 50.4% Melting point 141-144°C.

[0094] Preparation of deoxy-(2-iodoacetoxy)-mutriptyline (3)

[0095] Dissolve 1.08 g (6.54 mmol) of potassium iodid...

Embodiment 2

[0104] 14-Deoxy-[2-[2-[2-(piperidinyl)acetamido]-thiazole-4-methylthio]acetoxy]-mutriptyline (II 2 ) preparation

[0105] Refer to I I 1 The preparation method, by ( 5 ) reacted with hexahydropyridine, a white foamy solid with a yield of 65%. 1 HNMR (CDCl 3, 400 MHz): δ 10.42 (1H, br, NH), 6.79 (1H, s, H25), 6.51 ( 1H, dd, J 1 =10.8, J 2=17.2, H19), 5.79 (1H, d, J =8.4, C14), 5.39 (1H, d, J =10.8, C20), 5.24 (1H, d, J =17.6, C20), 3.83 (2H, s, H23), 3.38 (1H, m, H11), 3.18 (2H, s, H22), 3.06 (2H, s, H28), 2.52 (4H, br, 2× NCH 2 ), 2.39~2.05 (5H, m, H2, H4, H10, H13), 1.80~1.19 (20H, m, H1, H6, H7, H8, H15, H13,11-OH, H18, 3×CH 2 ), 0.89 (3H, d, J =6.8, H17), 0.75 (3H, d, J =6.8, H16); 13 CNMR (CDCl 3, 400 MHz): δ 217.10 (C3), 168.64 (C21), 157.83 (C27), 146.17 (C26), 139.08 (C24), 117.30 (C19), 111.32 (C20), 107.03 (C25), 74.61 (C11), 69.19 (C14), 61.89 (CH 2 NCH 2 ), 58.17 (C4), 56.68 (C28), 45.44 (C22), 45.38 (C9), 43.89 (C13), 41.72 (C12), 36.78 ...

Embodiment 3

[0107] 14-Deoxy-[2-[2-[2-(morpholinyl)acetamido]-thiazole-4-methylthio]acetoxy]-mutriptyline (II 3 ）

[0108] Refer to I I 1 The preparation method, by ( 5 ) reacted with morpholine, white foamy solid, yield 61%. 1 HNMR (CDCl 3, 400 MHz): δ 7.27 (CHCl 3 ), 6.81 (1H, s, H25), 6.50 (1H, dd, J 1 =11.2, J 2 =17.6, H19), 5.79 (1H, d, J =8.4, H14), 5.38 (1H, d, J =11.2, H20), 5.24 (1H, d, J =17.6, H20), 3.83 (2H, s, H23), 3.79 (4H, t, C H 2 OC H 2 , 3.38 (1H, m, H11), 3.27 (2H, s, H22), 3.05 (2H, s, H28), 2.64 (4H, br, CH 2 NCH 2 ), 2.39~2.05 (5H, m, H2, H4, H10, H13), 1.80~1.14 (16H, m, H1, H6, H7, H8, H15, H13, 11-OH, H18), 0.89 (3H, d, J =7.2, H17), 0.75 (3H, d, J =6.8, H16); 13 CNMR (CDCl 3, 400 MHz): δ 217.06 (C3), 168.61 (C21), 157.68 (C27), 146.27 (C26), 139.13 (C24), 117.25 (C19), 111.46 (C20), 107.04 (C25), 74.62 (C11), 69.28 (C14), 61.00 (CH 2 OCH 2 ), 59.18 (C4), 57.63 (C28), 53.52 (CH 2 NCH 2 ), 45.46 (C22), 44.84 (C9), 43.92 (C13), 41.7...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Melting pointaaaaaaaaaa
Login to View More

Abstract

The invention discloses a pleuromutilin derivate, a preparation method and medical use thereof. The pleuromutilin derivate is a compound, which is obtained by coupling pleuromutilin to alkyl acylamino-thiazole-4-methyl merecaptan with 2-different substitutional amino. Pharmacological experimental results show that: compared with the pleuromutilin, the pleuromutilin derivate disclosed by the invention has better antimicrobial and antibiotic resistant bacteria activities; and therefore, the compound is possibly applicable for curing a plurality of infection and inflammatory diseases on clinic.

Description

technical field [0001] The present invention relates to the field of medicine, in particular to a class of pleuromutilin derivatives and pharmaceutically acceptable salts thereof, their preparation methods, pharmaceutical compositions containing these derivatives and their pharmaceutical applications, especially in the preparation of antibacterial and applications in anti-drug-resistant bacteria. [0002] Background technique [0003] Pleuromutilin is a broad-spectrum diterpene antibiotic produced by submerged cultures of the higher fungi Basidiomycetes Pleurotus mutilus and Pleurotas passeck-rianus, mainly active against Gram-positive bacteria and mycoplasma . In 1951, Kavanagh et al first discovered, defined and isolated this crystalline antibacterial substance, and named it Pleuromutilin (Compound 1). [0004] In 1974, on the basis of pleuromutilin, the Sandoz Institute obtained a highly active animal-specific antibiotic tiamulin (compound 2, Tiamulin) through semi-syn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D277/46C07D277/40C07D417/12A61K31/5377A61K31/496A61K31/4439A61K31/427A61K31/426A61P31/04A61P11/00A61P1/00A61P13/02A61P15/00A61P17/00A61P25/00A61P19/08
Inventor 王新杨凌勇张丽颖高琦汪东庚陈广通赵育仇文倩陶金华赵喜
Owner 南通药享科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com